Head and Neck Cancer

Viome launches early detection test for oral and throat cancers

The test leverages mRNA technology and an artificial intelligence platform to detect biomarkers for oral and throat cancer with 95% specificity and 90% sensitivity rates, the firm said.

August 3, 2022

Sysmex Inostics touts liquid biopsy findings at ASCO

The featured data will show how the company's SafeSEQ cfHPV-DNA Test (HPV-SEQ) detects cell-free HPV DNA, enabling monitoring for patients with HPV and oropharyngeal squamous cell carcinoma (OPSCC), a type of head and neck cancer.

June 3, 2021

Google reports pathology AI helps predict survival in cancer patients

The deep-learning system was developed and tested using histopathology slides for patients with 10 cancer types -- including bladder cancer, invasive breast cancer, and head and neck squamous cell carcinoma -- drawing from publicly available data from the Cancer Genome Atlas (TCGA) program.

June 17, 2020

Naveris blood test spots recurrence of HPV cancers

The test is designed to identify tumor-modified viral HPV DNA. The prospective study, conducted by lead author Dr. Bhisham Chera of the University of North Carolina School of Medicine and colleagues, included 115 patients treated for HPV-related head and neck cancers who were tracked for recurrence for up to 3.5 years with imaging and fiber-optic nasopharyngeal endoscopy. The patients had the blood test before and during treatment and at post-treatment follow-up visits.

February 5, 2020

Agilent's PD-L1 test gets OK for head, neck cancer in Europe

The assay is approved for use as a companion diagnostic with the checkpoint inhibitor pembrolizumab (Keytruda, Merck), the company said in a statement. Keytruda is approved as a monotherapy or in combination with chemotherapy for the first-line treatment of metastatic or unresectable recurrent HNSCC in adults whose tumors express PD-L1 with a combined positive score of at least 1.

November 21, 2019

Sysmex offers SafeSeq breast, head and neck cancer panels

SafeSeq liquid biopsy delivers sensitivity down to five mutant molecules among 10,000 wildtype copies, or 0.05% mutant allele frequency, the company said.

September 29, 2019

Most Popular

Quest launches long-COVID testing panels for consumers

Ohio, Kentucky doctors convicted in scheme to bill Medicaid for unnecessary urinalysis testing

RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target

Quest Diagnostics offers suite of services for transplant patients and living donors

Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux

Rapid nirmatrelvir treatment in study reduced long-COVID risk

With LabCorp's lead, Mount Sinai dives into digital pathology

Philips Healthcare's IntelliSite Pathology Solution software is now being deployed across Mount Sinai's eight hospitals, using LabCorp's experience with the product as a guide for implementation, building on prior collaborative efforts. The plan is to enable Mount Sinai specialists to provide real-time pathology interpretations in the New York metropolitan area, with an initial focus on prostate tumors and other genitourinary malignancies and head and neck cancer. Mount Sinai pathologists will also provide national teleconsulting work for LabCorp's Dianon specialty pathology lab in the future.

June 17, 2019

Page 1 of 1